Drugs / Bifidobacterium triple viable powder
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06238349 | Jan → Jun 2024 | hyperbilirubinemia | Zhuhai Center for Maternal and Child Health Care | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium triple viable powder | “Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light” NCT06238349 ↗ |
| Known as | Peifeikang powder | “Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day.” NCT06238349 ↗ |
| Modality | Other / unclassified | “Bifidobacterium triple viable powder contains live bacteria” NCT06238349 ↗ |
| Route | Oral | “orally be given Bifidobacterium triple viable powder” NCT06238349 ↗ |